Page results
-
UCLH has recruited the first participant to an international trial in frontotemporal dementia (FTD), one of the most common causes of early-onset dementia.
-
A multi-disciplinary team involving UCLH and UCL has developed a way to monitor the progression of movement disorders using motion capture technology and AI.
-
UCLH is committed to not only treat patients’ illnesses but to provide an environment and an experience which contributes to patients’ general wellbeing.
-
Mark Emberton joined the board as a non-executive director on 1 September 2022. He is Professor of Intervention Oncology within the Division of Surgery and Dean of the Faculty of Medical Science at University College London.
-
Subtle changes in the brain, detectable through advanced imaging, blood and spinal fluid analysis, happen around twenty years before a clinical motor diagnosis in people with Huntington’s disease, a new study at UCLH and UCL has found.
-
Last year, UCLH Arts & Heritage and our resident doctor community worked collaboratively to run a series of 10 creative workshops looking at various art-making methods aimed at improving the wellbeing of doctors.
-
The first UK trial to test the benefits of proton beam therapy for certain patients with breast cancer has launched at UCLH.
-
Dr Hotton is a consultant neurologist with a special interest in movement disorders and the neurological care of patients with central nervous system tumours.
-
The UCLH trauma and orthopaedics team has reached a milestone of 1000 operations on hips and knees using the Mako robot.
-
UCLH doctor 1 of 10 international members elected to National Academy of Medicine
